Rapid Communication| Volume 36, ISSUE 5, P802-812.e1, May 01, 2014

Pneumococcal Vaccination in Europe: Schedule Adherence


      Nonadherence to recommended pneumococcal conjugate vaccine (PCV) schedules may have implications for protection against pneumococcal disease. In this commentary, we have assessed adherence to the recommended dosing schedules (the completion of the primary PCV and booster series) in different European countries. We found that adherence with the PCV schedule was lower than that for diphtheria-tetanus-acellular pertussis (DTaP) and that higher adherence was observed in countries where PCV vaccination is recommended and funded. Adherence with the booster dose is often lower than that with the primary series completion, and it is often given after the recommended age. These data highlight the need to encourage timely vaccination of children with PCV, in line with local immunization schedules. There is no single solution to improve adherence; actions need to be tailored to the context of individual countries through initiatives at the national, regional, and local levels and should target different stakeholders.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kaplan S.L.
        • Mason Jr, E.O.
        • Wald E.R.
        • et al.
        Decrease of invasive pneumococcal infections in children among 8 childrenʼs hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.
        Pediatrics. 2004; 113: 443-449
        • Whitney C.G.
        • Pilishvili T.
        • Farley M.M.
        • et al.
        Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.
        Lancet. 2006; 368: 1495-1502
        • Zhou F.
        • Shefer A.
        • Kong Y.
        • Nuorti J.P.
        Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004.
        Pediatrics. 2008; 121: 253-260
        • Myint T.T.
        • Madhava H.
        • Balmer P.
        • et al.
        The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.
        Adv Ther. 2013; 30: 127-151
        • Durando P.
        • Crovari P.
        • Ansaldi F.
        • et al.
        Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy.
        Vaccine. 2009; 27: 3459-3462
        • Stamboulidis K.
        • Chatzaki D.
        • Poulakou G.
        • et al.
        The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea.
        Pediatr Infect Dis J. 2011; 30: 551-555
        • Black S.B.
        • Shinefield H.R.
        • Ling S.
        • et al.
        Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.
        Pediatr Infect Dis J. 2002; 21: 810-815
        • Koshy E.
        • Murray J.
        • Bottle A.
        • et al.
        Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008.
        Thorax. 2010; 65: 770-774
        • Black S.
        • Shinefield H.
        • Fireman B.
        • et al.
        Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.
        Pediatr Infect Dis J. 2000; 19: 187-195
        • Eskola J.
        • Kilpi T.
        • Palmu A.
        • et al.
        Efficacy of a pneumococcal conjugate vaccine against acute otitis media.
        N Engl J Med. 2001; 344: 403-409
        • Griffin M.R.
        • Zhu Y.
        • Moore M.R.
        • et al.
        U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.
        N Engl J Med. 2013; 369: 155-163
        • Miller E.
        • Andrews N.J.
        • Waight P.A.
        • et al.
        Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.
        Lancet Infect Dis. 2011; 11: 760-768
      1. European Medicines Association. Prevnar: Summary of product characteristics. 2013; Accessed November 20, 2013.

        • Hug S.
        • Weibel D.
        • Delaporte E.
        • et al.
        Comparative coverage of supplementary and universally recommended immunizations in children at 24 months of age.
        Pediatr Infect Dis J. 2012; 31: 217-220
      2. Giotas A, Kotzia D, Grivea IN, et al. Timeliness of pneumococcal conjugate vaccination in Greece. Presented at: 30th Annual Meeting of the European Society for Paediatrics Infectious Diseases, May 8–12, 2012, Thessaloniki, Greece.

        • ICONA Working Group.
        ICONA 2008: National Vaccination Coverage Survey Among Children and Adolescents.
        Istituto Superiore di Sanità, Rome, Italy2009
      3. Eidgenössische Kommission für Impffragen (EKIF). Swiss vaccination plan 2012. Accessed January 31, 2013.

      4. Hellenic Ministry of Health & Social Solidarity.Ψ6Θ-Θ0Κ. Accessed 12 March 2013, 2013.

      5. Cozza V, Kanitz E, D’Ancona F, Giambi C. Impact of childhood pneumococcal vaccination programmes and activities for pneumococcal vaccines in the EU and EEA/EFTA countries. Accessed September 26, 2013.

      6. Eidgenössische Kommission für Impffragen (EKIF). Swiss vaccination plan 2013. Accessed September 26, 2013.

      7. Guthmann JP, Fonteneau L, Levy-Bruhl D. Measuring vaccination uptake in France: sources and current data [in French]. Accessed November 20, 2013.

        • Martinot A.
        • Cohen R.
        • Denis F.
        • et al.
        Annual trends (2008–2011) in early childhood vaccination coverage for the French population: the Vaccinoscopie study [in French].
        Arch Pediatr. 2013; 20: 837-844
        • World Health Organization
        Pneumococcal vaccines WHO position paper—2012.
        Wkly Epidemiol Rec. 2012; 87: 129-144
      8. Greenwood BM, Weber MW, Mulholland K. Childhood pneumonia - preventing the world’s biggest killer of children. Bull World Health Organ. 2007;85:502–503.

      9. Ruckinger S, Dagan R, Albers L, et al. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: A systematic review and meta-analysis. Vaccine. 2011;6:9600–9606.

        • Leask J.
        Target the fence-sitters.
        Nature. 2011; 473: 443-445
      10. World Health Organization, United Nations Childrenʼs Fund, World Bank. State of the world’s vaccines and immunization. Accessed September 26, 2013.